Studio per prevenire l'emicrania da cronicizzazione attraverso la previsione della risposta al trattamento con anticorpi anti-CGRP (PREDI-CGRP)
Studio di previsione o risposta al trattamento con anticorpi monoclonali anti-CGRP nell'emicrania
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The study consists of an initial visit coinciding with the start of treatment, a subsequent visit after 6 months of treatment and finally another after 12 months, coinciding with the end of treatment. In case of worsening after suspension, a clinical visit will be carried out at the time of worsening to evaluate the reintroduction of the drug and in case of reintroduction, a visit will be carried out after 3 months. If patients do not worsen, a visit will be made 6 months after completing treatment.
At each visit, demographic and clinical variables will be collected. In addition, 3 blood tests will be performed corresponding to the beginning of treatment, after 6 months and a month and a half from the last infiltration. Likewise, a brain MRI will be obtained prior to the start of treatment. These blood samples and neuroimaging data will be processed for subsequent analysis.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
Aragon
-
Zaragoza, Aragon, Spagna, 50009
- Hospital Clínico Universitario Lozano Blesa
-
-
Basque Country
-
Donostia / San Sebastian, Basque Country, Spagna, 20014
- Hospital Universitario Donostia
-
-
Cantabria
-
Santander, Cantabria, Spagna, 39008
- Hospital Universitario Marqués de Valdecilla
-
-
Castille and León
-
Valladolid, Castille and León, Spagna, 47010
- Hospital Clínico Universitario de Valladolid
-
-
Catalonia
-
Barcelona, Catalonia, Spagna, 08035
- Hospital Universitari Vall d'Hebron Research Institute
-
-
Madrid
-
Madrid, Madrid, Spagna, 28006
- Hospital Universitario de La Princesa
-
-
Valencia
-
Valencia, Valencia, Spagna, 46026
- Hospital Universitario Politécnico La Fe
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Patients aged between 18 and 65 years with a diagnosis of episodic or chronic migraine who, at the discretion of their neurologist and according to clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or its receptor (Erenumab) be included. These patients will come from 7 Headache Units in Spain belonging to the following hospitals:
- La Princesa University Hospital
- Vall d'Hebron University Hospital
- Marqués de Valdecilla University Hospital
- Valladolid University Clinical Hospital
- Donostia University Hospital
- Lozano Blesa University Clinical Hospital
- La Fe Polytechnic University Hospital
Descrizione
Inclusion Criteria:
- Patients aged between 18 and 65 years.
- Caucasian ethnicity.
- Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).
- Have at least one year of history of migraine.
- Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.
- Patients able to describe their clinical situation and the characteristics of their headache.
- Grant your informed consent.
Exclusion Criteria:
- Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.
- Neurological focus in the examination.
- Pregnancy or breastfeeding period.
- Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.
- Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.
- Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Patients with migraine under treatment with monoclonal antibodies against CGRP
Patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or else its receptor (Erenumab) will be included. |
The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication. Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia. Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Biomarkers of positive initial response to monoclonal antibodies
Lasso di tempo: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
Establish clinical, demographic, transcriptomic, genetic, molecular and/or radiological characteristics that allow predicting a positive initial response to monoclonal antibodies (biomarkers of therapeutic response). |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Sustained response factors
Lasso di tempo: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To analyze sustained response factors at the sociodemographic, clinical, transcriptomic, genetic, molecular and/or radiological level after the suspension of anti-CGRP drugs. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Sustained response after discontinuation of the anti-CGRP antibody
Lasso di tempo: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To quantify the proportion of patients who present a sustained response after discontinuation of the anti-CGRP antibody. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Non-maintained pharmacological response relation with biomarkers
Lasso di tempo: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To characterize whether the non-maintained pharmacological response is related to the variables previously characterized as predictors of chronicity. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Time until relapse after discontinuation of the anti-CGRP antibody
Lasso di tempo: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To determine the time until relapse after discontinuation of the anti-CGRP monoclonal antibody in those patients who, having presented a positive initial response, discontinue it. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Biomarkers of patients with high-frequency episodic migraine and chronic migraine
Lasso di tempo: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To validate possible transcriptomic, genetic, molecular and/or radiological characteristics that allow differentiation between patients with high-frequency episodic migraine and chronic migraine in a national multicenter cohort. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Ana Beatriz Gago Veiga, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Dolore
- Manifestazioni neurologiche
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Disturbi della cefalea, primaria
- Disturbi della cefalea
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Disturbi dell'emicrania
- Male alla testa
- Tecniche investigative
- Pesi e misure
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- PI 23- 3054
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual participant data (IPD) will not be shared with other researchers. This decision is based on data protection and confidentiality requirements in accordance with applicable European and national regulations (including GDPR). Given that this is a multicentre observational study conducted in routine clinical practice, access to IPD is restricted to the study investigators for the purposes of the predefined analyses.
Any potential secondary use of the dataset would only be considered in fully anonymized form and subject to prior ethical approval and compliance with applicable data protection legislation.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .